


Technical Information about N⁶-Phenyl-cAMP

Potent membrane-permeant, site-selective and PDE-resistant activator of cAMP-dependent protein kinases

Update: October 12, 2017 HU



Abbreviation: 6-Phe-cAMP

Formula	CAS No.	Molecular Weight	UV	BIOLOG Cat. No.
C ₁₆ H ₁₅ N ₅ O ₆ P·Na	[34051-30-4]	427.3	λ _{max} 288 nm / ε 20800 / pH 7	P 006

Name: N⁶-Phenyladenosine- 3', 5'- cyclic monophosphate

Description: 6-Phe-cAMP is an analogue of the natural signal molecule cyclic AMP in which one of the hydrogen atoms of the amino group in position 6 of the adenine moiety is replaced by a lipophilic phenyl ring.

Properties:

- One of the most potent activators of cAMP-dependent protein kinase isozymes which does not activate Epac
- Excellent selectivity between cAMP- and cGMP protein kinases
- High metabolic stability towards cyclic nucleotide-responsive phosphodiesterases¹
- Site-selective analogue with strong preference for the A-sites of PKA type I and type II²
- Suitable partner for synergistic activation of PKA I or II by pairs of analogues (please ask for corresponding information)
- High lipophilicity and good membrane permeability while still soluble in aqueous solvents

6-Phe-cAMP is an extraordinary potent and site-selective cAMP agonist with unusual high affinity for the A sites of PKA. When combined with analogues of corresponding B-site selectivity (e.g. Sp-5,6-DCI-cBIMPS, Cat. No. D 014) it is a powerful tool for synergistic activation of PKA type I and type II, respectively.

Furthermore, 6-Phe-cAMP does not activate Epac and thus can be used as an Epac-negative control.

Specification: Crystallized or lyophilized sodium salt. Other salt forms are available upon request. Equal concentrations of 6-Phe-cAMP can appear very different in volume due to sensitivity of the lyophilized form to humidity. The compound can even contract to small volume droplets. Normally the product is located in the conical bottom of the tube. Micromolar quantities are determined by UV at λ_{max}.

Purity: Typical analysis is better than 98% (HPLC / UV / 288 nm). The product is not sterile and has not been tested for endotoxins.

Stability and Storage: 6-Phe-cAMP has sufficient stability at room temperature and does not need special care during handling or shipment. Nevertheless, we recommend that the compound should be stored in the freezer, for longer storage periods preferably in freeze-dried form.


Toxicity and Safety: Since cyclic AMP has multiple tasks in every organism, it is very likely that lipophilic cAMP analogues will interfere with many cell regulation processes *in vivo*. However, due to the rather small quantities to work with, no health hazards have been reported. Nevertheless please keep in mind, that the *in vivo* properties of this compound are not sufficiently characterized up to now. Avoid skin contact or ingestion and allow only trained personnel to handle the product.

Our products are designed, developed and sold for research purposes only! They are intended for *in vitro* and nonhuman *in vivo* laboratory applications. Any other use requires approval of health authorities.

Not for drug, household or related uses!

Solubility: Detailed information on the solubility of 6-Phe-cAMP in water and various buffers are listed in the solubility chart below. Concentrations have been determined at ambient temperature and can be considered as minimum concentrations usually obtainable, however, slight batch-to-batch variations cannot be ruled out. When opening the tube please make sure that no substance is lost within the cap. Please rinse tube walls carefully and preferably use ultrasonic or vortex to achieve total and uniform mixing.

No.	Solvent	Solubility [mM]
I	H ₂ O	250
II	DMSO	250
III	DMF	250
IV	Ethanol 96%	10
V	Methanol	100
VI	PBS, pH 7.4	250
VII	100 mM Na ₂ HPO ₄ , pH 7.0	250
VIII	25 mM HEPES/NaOH, pH 7.2	250
IX	25 mM Tris/HCl, pH 7.4	250



Selected References for 6-Phe-cAMP:

Lu, D.; Aroonsakool, N.; Yokoyama, U.; Patel, H.H.; Insel, P.A., *Mol. Pharmacol.*, **84**, 787 - 793 (2013): "Increase in Cellular Cyclic AMP Concentrations Reverses the Pro-Fibrogenic Phenotype of Cardiac Myofibroblasts: A Novel Therapeutic Approach for Cardiac Fibrosis"

Jäger, R.; Russwurm, C.; Schwede, F.; Genieser, H.-G.; Koesling, D.; Russwurm, M., *J. Biol. Chem.*, **287**, 1210 – 1219 (2012): „Activation of PDE10 and PDE11 Phosphodiesterases“

Banales, J.M.; Masyuk, T.V.; Gradilone, S.A.; Masyuk, A.I.; LaRusso, N.F., *Hepatology*, **49**, 160 - 174 (2009): "The cAMP Effectors Epac and Protein Kinase A (PKA) are Involved in the Hepatic Cystogenesis of an Animal Model of Autosomal Recessive Polycystic Kidney Disease (ARPKD)"

Moll, D.; Prinz, A.; Gesellchen, F.; Drewianka, S.; Zimmermann, B.; Herberg, F.W., *J. Neural. Transm.*, **113**, 1015 - 1032 (2006): "Biomolecular Interaction Analysis in Functional Proteomics"

Kloss, S.; Srivastava, R.; Mulsch, A., *Mol. Pharmacol.*, **65**, 1440 - 1451 (2004): "Down-regulation of Soluble Guanylyl Cyclase Expression by Cyclic AMP is Mediated by mRNA-stabilizing Protein HuR"

Christensen, A. E.; Selheim, F.; de Rooij, J.; Dremier, S.; Schwede, F.; Dao, K. K.; Martinez, A.; Maenhaut, C.; Bos, J. L.; Genieser, H.-G.; Døskeland, S. O., *J. Biol. Chem.*, **278**, 35394 - 35402 (2003): "cAMP Analog Mapping of Epac1 and cAMP-Kinase. Discriminating Analogs Demonstrate that Epac and cAMP-Kinase Act Synergistically to Promote PC-12 Cell Neurite Extension"

Rehmann, H.; Schwede, F.; Døskeland, S.O.; Alfred Wittinghofer, A.; Bos, J.L., *J. Biol. Chem.*, **278**, 38548 - 38556 (2003): "Ligand-mediated Activation of the cAMP-responsive Guanine Nucleotide Exchange Factor Epac"

Mutafova-Yambolieva, V. N.; Smyth, L.; Bobalova, J., *Cardiovasc. Res.*, **57**, 217 - 224 (2003): "Involvement of Cyclic AMP-mediated Pathway in Neural Release of Noradrenaline in Canine Isolated Mesenteric Artery and Vein"

Muhonen, W. W.; Shabb, J. B., *Protein Sci.*, **9**, 2446 - 2456 (2000): "Resonant Mirror Biosensor Analysis of Type I(α) cAMP-dependent Protein Kinase B Domain-Cyclic Nucleotide Interactions"

Bradbury, N. A., *J. Cell. Physiol.*, **185**, 408 - 415 (2000): "Protein Kinase-A-mediated Secretion of Mucin from Human Colonic Epithelial Cells"

Schwede, F.; Maronde, E.; Genieser, H.-G.; Jastorff, B., *Pharmacol. Ther.*, **87**, 199 - 226 (2000): "Cyclic Nucleotide Analogs as Biochemical Tools and Prospective Drugs"

Qi, Z.; Hao, C.M.; Salter, K.; Redha, R.; Breyer, M.D., *Amer. J. Physiol.*, **276**, F622 - F628 (1999): "Type II cAMP-Dependent Protein Kinase Regulates Electronic Ion Transport in Rabbit Collecting Duct"

Singh, A.K.; Tasken, K.; Walker, W.; Frizzell, R.A.; Watkins, S.C.; Bridges, R.J.; Bradbury, N.A., *Am. J. Physiol.*, **275**, C562 - C570 (1998) : "Characterization of PKA Isoforms and Kinase-dependent Activation of Chloride Secretion in T84 Cells"

Mutafova-Yambolieva, V.N.; Keef, K.D., *Amer. J. Physiol.-Heart Circ. Physiol.*, **42**, H2687 - H2695 (1997): "Adenosine-Induced Hyperpolarization in Guinea Pig Coronary Artery Involves A(2B) Receptors and K-ATP Channels"

Maronde, E.; Middendorff, R.; Telgmann, R.; Müller, D.; Hemmings, B.; Tasken, K.; Olcese, J., *J. Neurochem.*, **68**, 770 - 777 (1997): "Melatonin Synthesis in the Bovine Pineal Gland is Regulated by Type II Cyclic AMP-Dependent Protein Kinase"

Torgersen, K.M.; Vaage, J.T.; Levy, F.O.; Hansson, V.; Rolstad, B.; Tasken, K., *J. Biol. Chem.*, **272**, 5495 - 5500 (1997): "Selective Activation of cAMP-Dependent Protein Kinase Type I Inhibits Rat Natural Killer Cell Cytotoxicity"

Huq, I.; Dostmann, W. R. G.; Øgreid, D. *Biochem. J.*, **316**, 337 - 343 (1996): "Isoleucine 368 is Involved in Low-Affinity Binding of N6-Modified cAMP Analogues to Site B of the Regulatory Subunit of cAMP-Dependent Protein Kinase I"

Sirotkin, A.V.; Makarevic, A.V.; Genieser, H.-G., *J. Physiol. Pharmacol.*, **47**, 134 (1996): "Effect of Regulators of Protein Kinase A on IGF-I and Steroid Secretion by Porcine Granulosa Cells in Vitro"

Ebright, R.H.; Le Grice, S.F.J.; Miller, J.P.; Krakow, J.S., *J. Mol. Biol.*, **182**, 91 - 107 (1995): "Analogues of Cyclic AMP that Elicit the Biochemically Defined Conformational Change in Catabolite Gene Activator Protein (CAP) but do not Stimulate Binding to DNA"

Gjertsen, B.T.; Mellgren, G.; Otten, A.; Maronde, E.; Genieser, H.-G.; Jastorff, B.; Vintermyr, O.; McKnight, G. S.; Døskeland, S.O., *J. Biol. Chem.*, **270**, 20599 - 20607 (1995): "Novel (Rp)-cAMPS Analogs as Tools for Inhibition of cAMP-Kinase in Cell Culture"

Connolly, B.J.; Willits, P.B.; Warrington, B.H.; Murray, K.J., *Biochem. Pharmacol.*, **44**, 2303 - 2306 (1992): "8-(4-Chlorophenyl)thio-cyclic AMP is a Potent Inhibitor of the cyclic GMP-specific Phosphodiesterase (PDEV)"

Steinberg, R.A.; Gorman, K.B.; Øgreid, D.; Døskeland, S.O.; Weber, I.T., *J. Biol. Chem.*, **266**, 3547 - 3553 (1991): "Mutations that Alter the Charge of Type I Regulatory Subunit and Modify Activation Properties of Cyclic AMP-dependent Protein Kinase from S49 Mouse Lymphoma Cells"

Houge, G.; Steinberg, R.A.; Øgreid, D.; Døskeland, S.O., *J. Biol. Chem.*, **265**, 19507 - 19516 (1990): "The Interaction of Catalytic Subunit (C) of cAMP-dependent Protein Kinase with Regulatory Subunit (RI) Having One or Both cAMP Sites Occupied"

Øgreid, D.; Ekanger, R.; Suva, R.H.; Miller, J.P.; Sturm, P.; Corbin, J.D.; Døskeland, S.O., *Eur. J. Biochem.*, **150**, 219 - 227 (1985): "Activation of Protein Kinase Isozymes by Cyclic Nucleotide Analogs Used Singly or in Combination"

References cited in this Technical Information:

- 1 Hong, C.I.; Tritsch, G.L.; Mittelman, A.; Hebborn, P.; Chheda, G.B., *J. Med. Chem.*, **18**, 465 (1975): "Synthesis and Antitumor Activity of 5'-Phosphates and Cyclic 3', 5' - Phosphates Derived from Biologically Active Nucleosides"
- 2 Øgreid, D.; Ekanger, R.; Suva, R.H.; Miller, J.P.; Døskeland, S.O., *Eur. J. Biochem.*, **181**, 19 - 31 (1989): "Comparison of the Two Classes of Binding Sites (A and B) of Type I and Type II Cyclic AMP-dependent Protein Kinases Using Cyclic Nucleotide Analogs"